Tizona: Christine O’Brien
Tizona Therapeutics’ Chief Operating Officer Christine O’Brien has become the company’s new Chief Executive Officer.
O’Brien joined Tizona in 2015 and has helped advance the company’s novel programs like TTX-080, the first anti-HLA-G antibody, into the clinic. By blocking the interaction of HLA-G with its receptors, TTX-080 prevents the suppression of both innate and adaptive immune activity and has the potential to enhance anti-tumor responses. It is currently enrolling patients in a Phase 1 clinical trial to evaluate the medicine as both a monotherapy and in combination with other agents in patients with advanced cancers.
In July Tizona entered into a transformative alliance with Gilead Sciences, with Gilead purchasing a 49.9% equity interest in Tizona with the exclusive option to acquire the remainder of the company.
